VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | BCMA 2+1 T-cell engager CC-93269 in patients with R/R myeloma

Luciano Costa, MD, PhD, of the UAB School of Medicine, Birmingham, AL, outlines preliminary results from the first Phase I clinical study of the B-cell maturation antigen (BCMA) 2+1 T-cell engager, CC-93269 in patients with relapsed or refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter